Lpath Granted Key U.S. Patent Related to Ocular Drug Program, iSONEP

     Lpath Granted Key U.S. Patent Related to Ocular Drug Program, iSONEP

Patent Provides Coverage for Lpath's Anti-S1P Antibody in the Treatment of a
Wide Variety of Ocular Disorders, Including Wet AMD

PR Newswire

SAN DIEGO, Jan. 22, 2014

SAN DIEGO, Jan. 22, 2014 /PRNewswire/ --Lpath, Inc. (NASDAQ: LPTN), the
industry leader in bioactive lipid-targeted therapeutics,  received official
notification from the U.S. Patent and Trademark Office that the company has
been issued another key patent supporting its iSONEP™ program. The newly
issued U.S. patent, No. 8,614,103, is entitled, "Compositions and Methods for
Treating Ocular Conditions." It claims methods of using monoclonal antibodies
(including iSONEP) that bind sphingosine-1-phosphate (S1P) in the treatment of
a wide variety of ocular conditions, including wet age-related macular
degeneration (AMD).

"This patent adds additional coverage in the U.S. for use of our anti-S1P
antibodies in the treatment of a wide range of ocular disorders and
complements another recently issued patent (US 8,444,970) and certain patent
claims we have been granted in Europe (European patent No. 1 948 234) for wet
AMD, cancer, and other conditions," said Roger Sabbadini, Lpath's vice
president, founder, and an inventor of the issued patent. "These three patents
together provide exclusivity in our pursuit of ocular disorders beyond wet AMD
where we believe aberrant levels of S1P may be involved in pathogenesis of
disease."

Lpath is conducting a Phase 2 clinical trial for iSONEP, the Nexus trial,
which is evaluating the anti-S1P antibody's safety and efficacy in wet-AMD
patients that have not responded well to existing anti-VEGF therapies
including Lucentis®, Avastin® and Eylea®. Lpath entered into an agreement with
Pfizer (NYSE: PFE) in 2010 that provides Pfizer an exclusive option for a
worldwide license to develop and commercialize iSONEP.

Additionally, Lpath is independently conducting a Phase 2 trial in renal cell
carcinoma patients with ASONEP™, an anti-S1P antibody that is formulated for
systemic delivery.

Both iSONEP and ASONEP are first-in-class therapeutics developed using Lpath's
ImmuneY2™ drug-discovery engine. Antibodies developed via this discovery
engine are designed to target bioactive signaling lipids, such as S1P, that
are involved in cancer, AMD, inflammatory and auto-immune disorders, and many
other diseases.

About Lpath's Patent Portfolio
Lpath has achieved a broad and deep intellectual property position in the
bioactive-lipid area and t its comprehensive patent portfolio now includes 29
issued patents and 27 patent applications in the U.S., with corresponding
international patents and applications. These patents primarily relate to the
use of reagents and methods designed to interfere with the actions of
bioactive lipids involved in human disease. Lpath's intellectual property
portfolio includes coverage of compositions of matter that specifically bind
to sphingolipids and sphingolipid metabolites. These compositions, including
antibodies, could be used in the diagnosis and treatment of various diseases
and disorders, including cardiovascular and cerebrovascular disease, cancer,
inflammation, autoimmune disorders, ocular disease, and angiogenesis.

Lpath has also obtained issued patent claims on sphingolipid targets (e.g.,
receptors and signaling sphingolipids) and methods for using such targets in
drug-discovery screening efforts.

The company believes that its patent portfolio provides broad and commercially
significant coverage of antibodies, receptors, enzymes, and other moieties
that bind to a lysolipid (or a sphingolipid metabolite) for diagnostic,
therapeutic, and screening purposes.

About Lpath
San Diego-based Lpath, Inc. (NASDAQ: LPTN), an antibody-platform company, is
the category leader in lipid-targeted therapeutics. The company's ImmuneY2™
drug-discovery engine has the unique ability to generate therapeutic
antibodies that bind to and inhibit bioactive lipids that contribute to
disease. The company has developed four drug candidates, two of which—iSONEP
for wet AMD and ASONEP for cancer—are currently being investigated in Phase 2
trials. The other candidates are an anti-LPA antibody, Lpathomab, that is
currently in IND-enabling studies for neuropathic pain and neurotrauma and an
anti-leukotriene antibody, Altepan, which is being studied in models of
respiratory disease. For more information, visit www.Lpath.com.

About Forward-Looking Statements
The Company cautions you that the statements included in this press release
that are not a description of historical facts are forward-looking statements.
These include statements regarding: the protection against competition
afforded by issued patents; the eventual commercial viability of the Company's
drug programs; and the Company's ability to complete additional discovery and
development activities for drug candidates utilizing its proprietary ImmuneY2
drug-discovery process. Actual results may differ materially from those set
forth in this press release due to the risks and uncertainties inherent in the
Company's business, including, without limitation: the results of the
Company's preclinical studies and clinical trials may not support further
clinical development and/or the commercialization of its drug candidates; the
Company may not successfully complete additional clinical trials for its
product candidates on a timely basis, or at all; the Company may fail to
obtain required governmental approvals for any of its drug candidates; the
Company may not be successful in maintaining its commercial relationship with
Pfizer Inc. or any third party that acquires Pfizer's exclusive option to
iSONEP; and the Company may not be able to secure the funds necessary to
support its preclinical-development and clinical-development plans. More
detailed information about the risk factors and uncertainties that may affect
the realization of forward-looking statements is set forth in the Company's
filings with the Securities and Exchange Commission (the "SEC"), including its
Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and its other
filings with the SEC. Such documents may be read free of charge on the SEC's
website at www.sec.gov. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this cautionary
statement, and the Company undertakes no obligation to revise or update this
press release to reflect events or circumstances after the date hereof. This
caution is made under the safe harbor provisions of Section 21E of the Private
Securities Litigation Reform Act of 1995.

CONTACT:
Scott R. Pancoast
President and CEO
Lpath, Inc.
858-926-3200
spancoast@lpath.com
INVESTOR CONTACTS:
Westwicke Partners, LLC
Stefan Loren, Ph.D.    Robert H. Uhl
Managing Director      Managing Director
(443) 213-0507         (858) 356-5932
sloren@westwicke.com    robert.uhl@westwicke.com

SOURCE Lpath, Inc.

Website: http://www.Lpath.com
 
Press spacebar to pause and continue. Press esc to stop.